Back to search results

Improving Vascular Function in Veterans with HFpEF

This study is looking at new ways to help Veterans with Heart Failure with Preserved Ejection Fraction (HFpEF), a type of heart failure where the heart pumps normally but doesn't fill properly. Researchers are testing L-Citrulline, BH4, and Atorvastatin to see if these medications can improve how blood vessels work and increase physical ability. You might be able to join if you are 18 or older, have HFpEF, and meet certain heart function and blood test requirements. The main goal is to see if these treatments improve blood vessel function, measured at the start and again after 90 days. The current status of this study is unclear.

Study design
This interventional study plans to enroll 90 participants. It will compare L-Citrulline, BH4, and Atorvastatin against placebo (an inactive substance).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 90 days, as blood vessel function is measured at baseline and Day 90.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06312748

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Recruiting
PHASE1Ages 18+InterventionalTreatment
VA Office of Research and Development
~90 participants
Updated 2026-04-23 on ClinicalTrials.gov
What's tested:L-CitrullinePlacebo for L-CitrullineBH4Placebo for BH4AtorvastatinPlacebo for Atorvastatin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Flow-mediated dilation (FMD)
Measured over Baseline, Day 90

Conditions

Heart Failure With Preserved Ejection Fraction
Inflammation

Explore related trials

Heart failure with normal ejection fraction

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • David W. Wray, PhD · PRINCIPAL_INVESTIGATOR · VA Salt Lake City Health Care System, Salt Lake City, UT

Who to contact

David W Wray, PhD
[email protected]
(801) 582-1565 · ext. 4162
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older and able to give written informed consent.
New York Heart Association (NYHA) functional class I, II, or III.
Left Ventricular Ejection Fraction (LVEF) \> 50%.
Plasma Brain Natriuretic Peptide (BNP) equal to or greater than 150 pg/mL or NT-proBNP equal to or greater than 600 pg/mL at Visit 1, or a BNP equal to or great than 100 pg/mL (or NT-proBNP equal to or greater than 400 pg/mL) and a hospitalization for heart failure within the last 12 months.

Exclusion

History of hypersensitivity or allergy to any lipophilic statin.
Prior EF \<50%.
NYHA Class IV.
Patients with HFpEF secondary to significant uncorrected primary valvular disease.
Active liver disease or unexplained persistent elevations in serum transaminase.
Women who are pregnant or may become pregnant.
Patients currently treated with antioxidants, nitrates, PDE-5 inhibitors, or statins.

What this trial measures

  • Flow-mediated dilation (FMD)Baseline, Day 90

    Peak change in brachial artery diameter (%)